IMMUNEX CORP /DE/

IMMUNEX CORP /DE/

Immunex Corporation, a Seattle-based biopharmaceutical company founded in 1981 (CIK 719529), specialized in developing therapeutic products for cancer, infectious diseases, and autoimmune disorders. The company's core product portfolio included Enbrel for rheumatoid arthritis, Leukine for bone marrow transplant patients, and Novantrone for leukemia and prostate cancer treatment. Immunex significantly expanded through a 1992-1993 merger with American Cyanamid's Lederle pharmaceutical units, dramatically increasing its revenue base. Key risks included heavy reliance on research and development investments and market competition in biopharmaceuticals. The company was acquired by Amgen, Inc. in July 2002 for $16 billion. View Immunex's SEC filings and financial history on Earnings Feed.